文献速递免疫规划传染病防控与疫情报告

中国广西2014-2025年突破性水痘感染回顾性队列研究

Breakthrough varicella infection: a retrospective cohort study based on large-scale real-world data in Guangxi, China, 2014-2025.
PubMed 文献 · Vaccine · 2026-06-17

该研究基于广西2014-2025年监测数据,分析575万余名水痘疫苗接种者中突破性感染动态。结果显示突破性感染率随接种后时间延长而上升,接种两剂次较一剂次风险显著降低。结论提示水痘疫苗免疫衰减,建议提高两剂次覆盖率并优化接种间隔。

要点

  • 突破性水痘累积发生率12个月为0.09%,72个月超1.00%,132个月达2.15%。
  • 与末剂接种后42天至<1年相比,间隔≥36个月突破性感染风险aHR=5.01。
  • 调整年龄、性别和年份后,两剂次较一剂次突破性感染风险aHR=0.29。

核心结论

  • 研究证实水痘疫苗接种后免疫衰减,突破性感染风险随时间延长而增加。
  • 提高两剂次覆盖率、优化接种间隔并将疫苗纳入国家免疫规划是减少突破性感染的关键。

研究设计与样本

  • 回顾性队列研究,分析中国广西2014至2025年监测数据。
  • 水痘病例来自中国疾病预防控制信息系统,接种记录来自广西免疫规划信息系统。
  • 共纳入5,755,799名水痘疫苗接种者。

主要发现

  • 70,013名(1.22%)接种者发生突破性感染,其中一剂次63,619名(1.71%),两剂次6,382名(0.31%),三剂次12名(0.15%)。
  • 突破性水痘累积发生率12个月为0.09%,72个月超过1.00%,132个月为2.15%。
  • 与末剂接种后42天至<1年相比,间隔12-<24个月aHR=1.31(95%CI:1.22-1.40),24-<36个月aHR=1.94(95%CI:1.82-2.07),≥36个月aHR=5.01(95%CI:4.71-5.32),均P<0.001。
  • 调整年龄、性别和日历年份后,接种两剂次较一剂次突破性感染风险aHR=0.29(95%CI:0.27-0.30,P<0.001)。

关键数值与推荐

  • 突破性水痘累积发生率采用Kaplan-Meier法估计。
  • 采用含时变变量的Cox比例风险模型评估突破性水痘相关因素。

临床怎么用

  • 应提高水痘疫苗两剂次覆盖率以降低突破性感染风险。
  • 需优化水痘疫苗接种间隔,并考虑将疫苗纳入国家免疫规划。
  • 对接种后长期人群需关注免疫衰减,适时评估加强免疫需求。

局限性

  • 原文未明确报告本研究的具体局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although varicella is a vaccine-preventable disease, the number of breakthrough infection cases has been increasing in recent years. However, data remain limited regarding the dynamics of breakthrough infections, especially in relation to vaccine dosage and dosing schedules. METHODS: This retrospective study analyzed surveillance data from Guangxi, China, from 2014 to 2025. Varicella cases were derived from the China Information System for Disease Control and Prevention (CISDCP), while varicella vaccination records were extracted from the Guangxi Immunization Information System (IIS). Cumulative incidence of breakthrough varicella was estimated using the Kaplan-Meier method, and cox proportional hazards models with time-varying variables were used to evaluate factors associated with breakthrough varicella. RESULTS: Of 5,755,799 varicella vaccine recipients, 70,013 (1.22%) had breakthrough infections: 63,619 (1.71%) among one-dose, 6382 (0.31%) among two-dose, and 12 (0.15%) among three-dose recipients. The cumulative breakthrough varicella rate was 0.09% at 12 months, exceeding 1.00% at 72 months, and 2.15% at 132 months. Compared with an interval of 42 days to <1 year since the last dose, the adjusted hazard ratios (aHRs) for breakthrough varicella increased progressively with longer intervals: 1.31 (95% CI: 1.22-1.40) for 12-<24 months, 1.94 (95% CI: 1.82-2.07) for 24-<36 months, and 5.01 (95% CI: 4.71-5.32) for ≥36 months (all P < 0.001). Receipt of a second dose was associated with a lower hazard than one dose (aHR = 0.29; 95% CI: 0.27-0.30; P < 0.001), after adjustment for age, sex, and calendar year. CONCLUSION: Our study confirms waning immunity after varicella vaccination. Increasing two-dose coverage, optimizing the vaccination interval, and including the vaccine in national programs are key to reducing breakthrough infections. Prospective studies with immune monitoring are needed to assess long-term protection and the optimal dosing interval.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wang J, Li S, Zhou W, et al. Breakthrough varicella infection: a retrospective cohort study based on large-scale real-world data in Guangxi, China, 2014-2025. Vaccine. 2026. PMID: 42308974. doi:10.1016/j.vaccine.2026.128838

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。